Home Tags TROP2

Tag: TROP2

Merck & Co Announces Phase 3 Trial Initiations for MK-2870/SKB264

Merck & Co/MSD has initiated a pivotal Phase 3 trials for of its investigational antibody-drug conjugates (ADC) candidate MK-2870/SKB264, an innovative TROP2-targeting ADC being...

Results of Preclinical Data for GQ1010 Confirm Potential for Best-In-Class TROP2-Targeted...

The trophoblast cell surface antigen 2 (TROP2), a transmembrane glycoprotein that plays a role in cell self-renewal, proliferation, and transformation and survival, is overexpressed in many forms of cancers independent of baseline levels of TROP2 expression.

Daiichi Sankyo and AstraZeneca Sign Collaboration with Lung Cancer Research Foundation;...

The Lung Cancer Research Foundation (LCRF), a leading nonprofit organization focused on funding innovative, high-reward research with the potential to extend survival and improve...

Combinations with Datopotamab Deruxtecan Show Promising Clinical activity in Treatment of...

Initial results from the TROPION-Lung02 Phase Ib trial demonstrated that that datopotamab deruxtecan (Dato-DXd), a specifically designed TROP2-directed DXd antibody drug conjugate (ADC) being...

Kelun-Biotech Signs Oncology Research Collaboration Agreement with Merck/MSD

Chinese clinical-stage biotech company Kelun-Biotech*,  a subsidiary of Sichuan Kelun Pharmaceutical, has signed an exclusive license agreement with Merck & Co/MSD to develop an...

Sacituzumab Govitecan Increases PFS for Patients With Most Common Type of...

Treatment with sacituzumab govitecan (Trodelvy®; Gilead Sciences), an antibody-drug conjugate (ADC), resulted in longer progression-free survival (PFS) compared to physician’s choice of chemotherapy in...
General images of ESMO 2019 Congress being held in Barcelona, Spain, September 27 - October 1, 2019. Courtesy European Society for Medical Oncology (ESMO). Used with Permission.

ESMO 2020: Late-Breaking Data for HER3 Directed ADC Patritumab Deruxtecan in...

Data for patritumab deruxtecan (U3-1402; Daiichi Sankyo) and fam-trastuzumab deruxtecan-nxki* (Enhertu®; Daiichi Sankyo/AstraZeneca), two antibody-drug conjugates (ADC) based on Daiichi Sankyo's proprietary DXd ADC...

Daiichi Sankyo and AstraZeneca Agree on Global Development and Commercialization for...

Daiichi Sankyo and AstraZeneca confirmed entering into a global development and commercialization agreement for datopotamab deruxtecan also know as DS-1062, a TROP2 directed DXd...

ASCO 2020 – Advancing Antibody-drug Conjugates: Sacituzumab Govitecan

With a growing number of antibody-drug conjugates being approved by regulatory agencies around the world and promising clinical benefits seen in investigational agents, the...
Featured image: An aerial view of the Yangtze River Delta/Shanghai in the southern Jiangsu province and northern Zhejiang province. Photo Courtecy: 2015 - 2020 © VCG/Gettyimages. Used with permission.

Everest Medicines to Initiate a Registration Study in China for Sacituzumab...

China-based Everest Medicines, a biopharmaceutical company focused on developing and commercializing transformative products, address critical unmet medical needs for patients in Greater China and...

X